Personalized care platform Mymee provides a personalized trial and care platform for autoimmune disease and long COVID, presenting a potential upsell or integration opportunity with hospitals and clinics seeking patient-centric management tools.

Strategic partnerships Recent collaboration with covidCAREgroup signals openness to partnerships that combine nutritional guidance and patient self-tracking, suggesting fertile ground for co-marketing and bundled solutions.

Award-winning traction World Changing Ideas award from Fast Company enhances credibility; leverage this recognition in outreach to healthcare networks and grant-funded programs seeking innovative digital health solutions.

Early-stage fintech-esque funding Raised 8.7M in funding with a small team, indicating efficiency and potential for scalable deployment; target health systems and payer partnerships that value cost-effective digital health platforms.

Low revenue, high potential Revenue in the under 1M range but with a focused niche in autoimmune and long COVID management; explore pilot programs with specialty clinics, patient advocacy groups, and research institutions to validate and expand adoption.